Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2024-06-18 Regulatory Filings
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma AG announces updated guidance
Regulatory Filings Classification · 98% confidence The document is an 'Ad-hoc announcement' dated June 18, 2024, disclosing 'inside information' under MAR Regulation (EU) No 596/2014. The core content is the announcement that Heidelberg Pharma AG has 'adjusted its guidance for the current fiscal year' (2024), detailing changes in expected sales, operating expenses, operating result (EBIT), and cash requirements. This is a direct communication of updated financial forecasts and operational outlook, which is characteristic of an Earnings Release (ER) or a specific update related to financial performance guidance. Since it is an update to guidance rather than the initial release of quarterly results, and it focuses purely on financial projections/changes, 'ER' (Earnings Release) is the most appropriate fit among the provided options, as it covers the announcement of periodical financial results/updates. It is not a full report (10-K or IR), nor a transcript (CT), nor a management discussion (MDA), but a direct guidance update.
2024-06-18 English
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Report Publication Announcement Classification · 99% confidence The document is a press release dated May 23, 2024, announcing that Heidelberg Pharma AG management will participate and present at several scientific conferences (Oncology Innovation Forum, ASCO, BIO International Convention, Jefferies Global Healthcare Conference) scheduled for May and June 2024. It details the dates, locations, and specific presentation/meeting schedules. This type of announcement, which informs the public about management's planned participation in industry events, is best classified as a general corporate announcement or news release. Since there is no specific category for 'Conference Participation Announcement,' and it is not a formal regulatory filing like a 10-K, ER, or IR, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate news releases that don't fit elsewhere, especially when disseminated via a news service like EQS.
2024-05-23 English
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 20.06.2024 in Ladenburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 98% confidence The document is explicitly titled 'Bekanntmachung der Einberufung zur Hauptversammlung' (Announcement of the Convocation to the General Meeting) and repeatedly refers to the 'ordentlichen virtuellen Hauptversammlung' (Ordinary Virtual General Meeting) scheduled for June 20, 2024. The agenda items (Tagesordnung) include voting on the approval of financial statements, discharge of management/supervisory boards, auditor appointment, and capital structure changes (Genehmigtes Kapital). This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM) to inform them and solicit their votes, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI) or, more broadly, the AGM announcement itself. Since the document is an official invitation and agenda setting the stage for the AGM, 'AGM-R' (AGM Information) is the most fitting primary classification, as it covers presentations and materials shared during the AGM, and this announcement precedes it. 'PSI' is also highly relevant, but 'AGM-R' captures the core event being announced. Given the context of German corporate law announcements ('AktG', 'Hauptversammlung'), AGM-R is the standard classification for the convocation notice.
2024-05-13 German
Q1 statement / Q1 financial report 2023/2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Management Statement on the First Three Months of 2024' for Heidelberg Pharma AG. It provides a comprehensive overview of the company's financial performance, including detailed income statements, balance sheet data, cash flow analysis, and management commentary for the period ending February 29, 2024. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report (IR). Q1 2024
2024-04-29 English
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
Interim / Quarterly Report Classification · 95% confidence The document is an 'Interim Management Statement' for the first three months of 2024. It contains substantive financial data, including a detailed table of key figures (unaudited) for Q1 2024 vs Q1 2023, balance sheet information, and cash flow statements. While it mentions that a conference call will not take place and provides a link to the full interim financial statements, the document itself provides sufficient financial analysis and data to qualify as an Interim/Quarterly Report (IR) rather than just an announcement (RPA). Q1 2024
2024-04-25 English
Q1 Mitteilung / Q1 Finanzbericht 2023/2024
Earnings Release Classification · 99% confidence The document explicitly states it reports on the 'ersten drei Monate 2024' (first three months of 2024) and provides detailed consolidated financial figures (Umsatzerlöse, Periodenfehlbetrag, Bilanzsumme) for this period (December 1, 2023 – February 29, 2024). This structure, covering a period shorter than a full year and containing comprehensive financial statements and management discussion, aligns perfectly with the definition of an Interim/Quarterly Report. The text also mentions that a conference call will not take place, distinguishing it from a Call Transcript (CT), and it is a full report, not just a brief announcement (ruling out RPA/ER). The German term used for this type of report is often 'Zwischenmitteilung' (Interim Report). Q1 2024
2024-04-25 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.